MobiHealth News September 16, 2022
Emily Olsen

The Rhythm Evaluation for AntiCoagulaTion (REACT-AF) trial will study a “pill-in-pocket” method of stroke prevention for patients with atrial fibrillation. Some participants will monitor for AFib using an Apple Watch and take blood thinners as needed.

Late last month, Northwestern University and Johns Hopkins University announced they had received about $37 million from the National Heart, Lung and Blood Institute to study a new approach to stroke prevention in patients with atrial fibrillation, an irregular heart rhythm.

The funds will support the Rhythm Evaluation for AntiCoagulaTion (REACT-AF) trial, a seven-year study that will provide some patients with an Apple Watch to monitor for AFib. They’ll be able to take blood thinners in response to a prolonged episode, while patients in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, Health System / Hospital, Interview / Q&A, Provider, Survey / Study, Technology, Trends, Wearables
Related Articles:
Wearable electrical nerve stimulation device eases long COVID pain and fatigue, say researchers
Singapore tackling chronic diseases with wearables
Researchers use fitness tracker data and machine learning to detect bipolar disorder mood swings
Oura Ring Is ‘Like An Apple Product’ And Could Take Key Health Metric Mainstream
Wearable ultrasound sensor revolutionizes continuous blood pressure monitoring

Share This Article